Group 1 - The core point of the article is that Xiansheng Pharmaceutical (02096.HK) has seen a stock increase of 6.33% following the announcement of a partnership with NextCure for the global development and sales of the cancer drug SIM0505, excluding Greater China [1] - Xiansheng could receive up to $745 million in upfront and milestone payments, in addition to sales royalties from the partnership [1]